Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
BMC Complement Altern Med ; 19(1): 10, 2019 Jan 08.
Artigo em Inglês | MEDLINE | ID: mdl-30621705

RESUMO

BACKGROUND: ChondroT, a new herbal medication, consists of the water extracts of Osterici Radix, Lonicerae Folium, Angelicae Gigantis Radix, Clematidis Radix, and Phellodendri Cortex (6:4:4:4:3). We previously reported that ChondroT showed significant anti-arthritis and anti-inflammatory effects. METHODS: This study was designed to evaluate the effect of ChondroT on hyperuricemia. First, the effect of ChondroT was evaluated on xanthine oxidase (XOD) activity in vitro. The anti-hyperuricemic effect of ChondroT was also studied in potassium oxonate (PO)-induced hyperuricemic model mice. Uric acid (UA) and XOD were evaluated in the serum, urine, and liver of the mice. In addition, we measured serum creatinine (Cr) and blood urea nitrogen (BUN) levels as well as mRNA expression of the mouse urate transporter 1 (mURAT1) to evaluate kidney function and urate excretion in hyperuricemic mice. RESULTS: ChondroT showed in vitro XOD inhibitory activity in a dose-dependent manner (P < 0.05). We demonstrated that ChondroT (37.5, 75 and 150 mg/kg) significantly reduced serum UA (P < 0.01 and P < 0.001, respectively), and upregulated urinary UA (P < 0.001, respectively) in PO-induced hyperuricemic mice. In addition, ChondroT (75 and 150 mg/kg) significantly reduced Cr (P < 0.05 and P < 0.01, respectively), BUN (P < 0.05 and P < 0.001, respectively), GOT (P < 0.05 and P < 0.01, respectively), and GPT (P > 0.05 and P < 0.05, respectively) levels in PO-induced hyperuricemic mice. ChondroT (75 and 150 mg/kg) also significantly downregulated serum (P < 0.05) and liver (P < 0.05) XOD activity. Compared to the hyperuricemic mice, the ChondroT (37.5, 75, and 150 mg/kg)-treated mice showed decreased mURAT1 protein expression level. CONCLUSION: ChondroT displayed anti-hyperuricemic effects by regulating XOD activity and kidney mURAT1.


Assuntos
Regulação para Baixo/efeitos dos fármacos , Medicamentos de Ervas Chinesas/administração & dosagem , Hiperuricemia/tratamento farmacológico , Transportadores de Ânions Orgânicos/genética , Ácido Oxônico/efeitos adversos , Xantina Oxidase/genética , Animais , Creatinina/sangue , Avaliação Pré-Clínica de Medicamentos , Humanos , Hiperuricemia/induzido quimicamente , Hiperuricemia/genética , Hiperuricemia/metabolismo , Rim/efeitos dos fármacos , Rim/fisiopatologia , Masculino , Camundongos , Camundongos Endogâmicos ICR , Transportadores de Ânions Orgânicos/metabolismo , Ácido Úrico/sangue , Xantina Oxidase/sangue
2.
Mediators Inflamm ; 2014: 406514, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24948847

RESUMO

Toll-like receptor (TLR) ligands are being developed for use as vaccine adjuvants and as immunomodulators because of their ability to stimulate innate and adaptive immune responses. Flagellin, a TLR5 ligand, was reported to show potent mucosal vaccine adjuvant activity. To identify ligands that potentiate the adjuvant activity of flagellin, we screened a plant library using HEK293T cells transiently cotransfected with phTLR5 and pNF- κ B-SEAP plasmids. The 90% EtOH extract from Croton tiglium showed significant NF- κ B transactivation in a TLR5-independent manner along with the increase of a flagellin activity. We have studied to characterize an active component from Croton tiglium and to elucidate the action mechanisms. Phorbol 12-myristate 13-acetate (PMA) was isolated as an active component of Croton tiglium by activity-guided fractionation, column chromatography, HPLC, NMR, and MS. PMA at a range of nM induced PKC-dependent NF- κ B activation and IL-8 production in both TLR5- and TLR5+ assay systems. In in vivo mouse vaccination model, PMA induced antigen-specific IgG and IgA antibody responses and increased IL-12 production corresponding to T cell responses in spleen lymphocytes. These results suggest that PMA would serve as an efficacious mucosal vaccine adjuvant.


Assuntos
Adjuvantes Imunológicos/química , Transdução de Sinais , Acetato de Tetradecanoilforbol/química , Receptores Toll-Like/metabolismo , Animais , Células CACO-2 , Núcleo Celular/metabolismo , Croton/química , Citosol/metabolismo , Flagelina/química , Células HEK293 , Humanos , Interleucina-8/metabolismo , Ligantes , Linfócitos/citologia , Camundongos , Camundongos Endogâmicos BALB C , NF-kappa B/metabolismo , Extratos Vegetais/química , Baço/citologia , Linfócitos T/imunologia , Receptor 5 Toll-Like/metabolismo , Ativação Transcricional , Vacinas
3.
Arch Pharm Res ; 33(5): 787-92, 2010 May.
Artigo em Inglês | MEDLINE | ID: mdl-20512479

RESUMO

Vibrio vulnificus (V. vulnificus) is a useful model for bacterial septicemia as the bacterial infection generates a wide pathogenic spectrum in addition to a high mortality rate. This study was aimed at investigating the effects of genistein on the growth, cytotoxicity, adhesion, and the mouse mortality caused by V. vulnificus. The results of our study indicated that genistein (50 or 100 mg/L) effectively minimized the morphologic damages and inhibited acute death of HeLa cells by V. vulnificus. Strikingly, genistein significantly inhibited the adhesion of V. vulnificus to HeLa cells. This report confirmed that genistein showed bacteriostatic activity against V. vulnificus, but it did not exhibit any bactericidal activity. Nevertheless, genistein (20 mg/kg) effectively decreased CD-1 mice mortality caused by V. vulnificus infection.


Assuntos
Aderência Bacteriana/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Genisteína/farmacologia , Genisteína/uso terapêutico , Vibrioses/tratamento farmacológico , Vibrio vulnificus/efeitos dos fármacos , Animais , Antibacterianos/farmacologia , Antibacterianos/uso terapêutico , Células HeLa , Humanos , Camundongos , Camundongos Endogâmicos , Testes de Sensibilidade Microbiana/métodos , Vibrioses/mortalidade , Vibrio vulnificus/crescimento & desenvolvimento , Vibrio vulnificus/patogenicidade
4.
J Microbiol ; 46(6): 737-43, 2008 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19107405

RESUMO

Vibrio vulnificus, a good model organism of bacterial septicemia, causes fatal septicemia manifesting a fulminating course and a high mortality rate within days. In order to identify new natural substances preventing V. vulnificus infection, a plant library was screened for inhibiting cytotoxicity to host cells by using Trypan blue staining and LDH assay. We found that Polygoni Cuspidati Radix potently suppressed the acute death of HeLa and RAW264.7 cells in a dose dependent manner. Further studies revealed that Polygoni Cuspidati Radix inhibited V. vulnificus growth and survival in HI broth and seawater, respectively. We confirmed that Polygoni Cuspidati Radix contained high level of emodin by thin layer chromatography (TLC). Emodin showed direct antibacterial activity against V. vulnificus. In addition, emodin prevented the morphologic damages and acute death of HeLa cells caused from V. vulnificus. The safety of Polygoni Cuspidati Radix and emodin to host cells was confirmed by MTT assay. Polygoni Cuspidati Radix and emodin protected mice from V. vulnificus infection.


Assuntos
Emodina/farmacologia , Fallopia japonica/química , Extratos Vegetais/farmacologia , Vibrioses/tratamento farmacológico , Vibrio vulnificus/efeitos dos fármacos , Animais , Técnicas Bacteriológicas , Bioensaio , Linhagem Celular , Sobrevivência Celular , Meios de Cultura , Emodina/uso terapêutico , Células HeLa , Humanos , Camundongos , Extratos Vegetais/química , Extratos Vegetais/uso terapêutico , Água do Mar/microbiologia , Vibrioses/microbiologia , Vibrioses/mortalidade , Vibrio vulnificus/crescimento & desenvolvimento , Vibrio vulnificus/patogenicidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA